Bimzelx Trial Win Raises New Questions For AbbVie Skyrizi Outlook

Simply Wall St.03-14 22:22

UCB reported that its arthritis drug Bimzelx outperformed AbbVie’s Skyrizi in a head to head clinical trial in psoriatic arthritis. The trial result introduces a new competitive challenge for one of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619991124?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285","is_english":true,"pubTime":"2026-03-14 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619991124","market":"nz","top_or_hot":-1,"title":"Bimzelx Trial Win Raises New Questions For AbbVie Skyrizi Outlook","media":"Simply Wall St.","content":"<div>\n<p>UCB reported that its arthritis drug Bimzelx outperformed AbbVie’s Skyrizi in a head to head clinical trial in psoriatic arthritis. The trial result introduces a new competitive challenge for one of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/bimzelx-trial-win-raises-new-questions-for-abbvie-skyrizi-ou\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bimzelx Trial Win Raises New Questions For AbbVie Skyrizi Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBimzelx Trial Win Raises New Questions For AbbVie Skyrizi Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-14 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/bimzelx-trial-win-raises-new-questions-for-abbvie-skyrizi-ou><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>UCB reported that its arthritis drug Bimzelx outperformed AbbVie’s Skyrizi in a head to head clinical trial in psoriatic arthritis. The trial result introduces a new competitive challenge for one of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/bimzelx-trial-win-raises-new-questions-for-abbvie-skyrizi-ou\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1934455863.HKD","symbol_name":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/bimzelx-trial-win-raises-new-questions-for-abbvie-skyrizi-ou","article_id":"2619991124","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/bimzelx-trial-win-raises-new-questions-for-abbvie-skyrizi-ou","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619991124","pubTimestamp":1773498171,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"UCB reported that its arthritis drug Bimzelx outperformed AbbVie’s Skyrizi in a head to head clinical trial in psoriatic arthritis.\nThe trial result introduces a new competitive challenge for one of NYSE:ABBV’s key immunology products in an important inflammatory disease indication.\nEarly commentary points to limited immediate sales impact, and investors are watching how this could influence future positioning of Skyrizi within psoriatic arthritis.\n\nFor context, AbbVie, ticker NYSE:ABBV, has...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","ABBV":"艾伯维公司","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4581":"高盛持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","BK4559":"巴菲特持仓","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD"},"translate_title":"Bimzelx试验胜利对AbbVie Skyrizi前景提出了新问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1.5},"content_text":"UCB reported that its arthritis drug Bimzelx outperformed AbbVie’s Skyrizi in a head to head clinical trial in psoriatic arthritis. The trial result introduces a new competitive challenge for one of NYSE:ABBV’s key immunology products in an important inflammatory disease indication. Early commentary points to limited immediate sales impact, and investors are watching how this could influence future positioning of Skyrizi within psoriatic arthritis.  For context, AbbVie, ticker NYSE:ABBV, has built a large part of its investment story around immunology treatments such as Skyrizi. Psoriatic arthritis is a core indication in this franchise, so a head to head result that favors a rival therapy sits squarely in the middle of an area investors track closely. Against a backdrop of ongoing competition in inflammatory diseases, this kind of data can shape how physicians compare different options over time. Looking ahead, you may want to watch for follow up data, guideline discussions, and any comments from AbbVie on how it plans to position Skyrizi versus Bimzelx in psoriatic arthritis. Market reaction can evolve as payers, physicians, and patients digest head to head results, so these touchpoints could help clarify whether this is mainly a signaling event or something that later affects prescribing trends within AbbVie’s immunology portfolio. Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie. NYSE:ABBV Earnings & Revenue Growth as at Mar 2026 📰 Beyond the headline: 5 risks and 2 things going right for AbbVie that every investor should see. AdvertisementQuick Assessment  ⚖️ Price vs Analyst Target: At US$219.68 versus an analyst target of about US$248.86, AbbVie trades roughly 12% below consensus. ✅ Simply Wall St Valuation: Simply Wall St flags AbbVie as trading about 41% below its estimated fair value. ❌ Recent Momentum: The 30 day return of about 0.55% decline signals slightly negative short term momentum.  There is only one way to know the right time to buy, sell or hold AbbVie. Head to Simply Wall St's\ncompany report for the latest analysis of AbbVie's Fair Value. Key Considerations  📊 Bimzelx outperforming Skyrizi in psoriatic arthritis directly challenges a key immunology product that features heavily in AbbVie’s story. 📊 Investors may want to monitor psoriatic arthritis market share data, management commentary on Skyrizi positioning, and any updates to treatment guidelines referencing the head to head trial. ⚠️ Existing flags such as a high debt load and questions around dividend coverage may compound concerns if investors see pressure on a core immunology revenue stream.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete AbbVie analysis. Alternatively, you can visit the\ncommunity page for AbbVie to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619991124","isCrawlerRequest":true}